MALT-лимфома с поражением легкого: клиническое наблюдение и обзор литературы

А.К. Морозова, Н.Г. Габеева, Е.Е. Звонков

ФГБУ «Гематологический научный центр» МЗ РФ, Москва, Российская Федерация


РЕФЕРАТ

В статье описывается редкое клиническое наблюдение MALT-лимфомы легкого, а также представлен обзор литературы. У больной пожилого возраста с MALT-лимфомой легкого была успешно проведена химиотерапия по программе R-B (ритуксимаб + бендамустин). После 6 курсов R-B получена стойкая ремиссия опухоли при минимальной токсичности и хорошей переносимости лечения.


Ключевые слова: MALT-лимфома легкого, химиотерапия, бендамустин.

Читать статью в PDF pdficon
ЛИТЕРАТУРА
  1. Cadranel J., Wislez M., Antoine M. et al. Primary pulmonary lymphoma. Eur. Respir. 2002; 20: 750–62.
  2. Isaacson P., Wright D.H. Malignant lymphoma of mucosa associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983; 52: 1410–6.
  3. Zinzani P.L., Vittorio Stefoni V., Musuraca G. et al. Fludarabine-Containing Chemotherapy as Frontline Treatment of Nongastrointestinal Mucosa-Associated Lymphoid Tissue Lymphoma. Cancer 2004; 100(10): 2190–4.
  4. Hui H., Zhi-wei L., Chun-guo J. et al. Clinical and prognostic characteristics of pulmonary mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 23 cases in a Chinese population. Med. J. 2011; 124(7): 1026–30.
  5. Воробьев А.И. Руководство по гематологии. Т. 2. М.: Ньюдиамед, 2003: 92–100. [Vorobyev A.I. Rukovodstvo po gematologii. T. 2 (Manual of hematology, Vol. 2). M.: Nyudiamed, 2003: 92–100.]
  6. Программное лечение заболеваний системы крови. Под ред. В.Г. Сав- ченко. Т. 2. М.: Практика, 2012: 579–93. [Programmnoye lecheniye zabolevaniy sistemy krovi. Pod red. V.G. Savchenko. T. 2 (Program therapy for hematological disorders. Ed. by V.G. Savchenko. 2). M.: Praktika, 2012: 579–93.]
  7. Zvonkov E., Krasilnikova B., Magomedova A. et al. FMC/FMC-R regimens efficiency in treatment primary extragastric MALT-lymphomas. Abstract book 2007; 92(1): 444.
  8. Красильникова Б.Б., Звонков Е.Е., Кравченко С.К. и др. Первый опыт применения программ FNC и FNC-R в лечении первичной лимфоцитомы орбиты. Гематол. и трансфузиол. 2008; 6: 3–7. [Krasilnikova B.B., Zvonkov Ye.Ye., Kravchenko S.K. i dr. Pervyy opyt primeneniya programm FNC i FNC-R v lechenii pervichnoy limfotsitomy orbity (Initial experience with FNC and FNC-R programs usage in therapy for primary orbital lymphocytoma. In: Hematol. & transfuziol.). Gematol. i transfuziol. 2008; 6: 3–7.]
  9. Yoon R.G., Kim M.Y., Songb J.W. Primary Endobronchial Marginal Zone B-Cell Lymphoma of Bronchus-Associated Lymphoid Tissue: CT Findings in 7 Patients. Korean J. Radiol. 2013; 14(2): 366–74.
  10. Zucca E., Conconi A., Laszlo D. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. Clin. Oncol. 2013; 31(5): 565–72.
  11. Domingo S., Canales M., Nicolas C. et al. Bendamustine and rituximab as first line treatment for patients with MALT lymphoma. An interim report of a phase 2 trial in Spain (MALT-2008–10). 11th International Conference on Malignant Lymphoma. Lugano, 2011. Abstract 299.
  12. Cordier J.F., Chailleux E., Lauque D. Primary pulmonary lymphomas. A clinical study of 70 cases in nonimmunocompromised patients. Chest 1993; 103(1): 201–8.
  13. Imai Н., Sunaga N., Kaira K. et al. Clinicopathological Features of Patients with Bronchial-Associated Lymphoid Tissue Lymphoma. Med. 2009; 48: 301–6.
  14. Thieblemont C., Berger F., Dumontet C. et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2013; 2000(95): 802–6.
  15. Borie R., Wislez M., Thabut G. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. Respir. J. 2009; 34: 1408–16.
  16. Troch M., Streubel B., Petkov V. et al. Does MALT Lymphoma of the Lung Require Immediate Treatment? An Analysis of 11 Untreated Cases with Longterm Follow-up. Anticancer Res. 2007; 27: 3633–8.
  17. Zinzani P.L., Magagnoli M., Galieni P. et al. Nongastrointestinal LowGrade Mucosa-Associated Lymphoid Tissue Lymphoma: Analysis of 75 Patients. Clin. Oncol. 1999; 17: 1254–8.
  18. Kocaturk C.I., Seyhan E.C., Zeki M. et al. Primary pulmonary nonHodgkin’s lymphoma: ten cases with a review of the literature. Toraks. 2012; 60(3): 246–53.
  19. Zinzani P.L., Pellegrini C., Gandolfi L. et al. Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantronecontaining regimens. Oncol. 2012 Dec 5. doi: 10.1002/hon.2039.
  20. Brown J.R., Friedberg J.W., Feng Y. et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. J. Haematol. 2009; 145(6): 741–8.
  21. Prabhash K., Vikram G.S., Nair R. et al. Fludarabine in lymphoproliferative malignancies: a single-centre experience. Med. J. India 2008; 21(4): 171–4.
  22. Rummel M.J., Kaiser U., Balser C. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas — Final Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting Abstracts 2010; 116: 856.
  23. Rummel M.J., Niederle N., Maschmeyer G. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 noninferiority trial. Lancet, Early Online Publication, 20 February 2013. doi: 10.1016/ S0140-6736(12)61763.